Antisickling Agents

• 

  Subject Areas on Research

  • A systematic review of barriers and interventions to improve appropriate use of therapies for sickle cell disease. 
  • Adherence to hydroxyurea therapy in children with sickle cell anemia. 
  • Advances in the Treatment of Sickle Cell Disease. 
  • An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. 
  • Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease. 
  • Caring for patients with sickle cell disease in North Carolina. 
  • Design, Synthesis, and Investigation of Novel Nitric Oxide (NO)-Releasing Aromatic Aldehydes as Drug Candidates for the Treatment of Sickle Cell Disease. 
  • Effect of myeloablative bone marrow transplantation on growth in children with sickle cell anaemia: results of the multicenter study of haematopoietic cell transplantation for sickle cell anaemia. 
  • Effect of propranolol as antiadhesive therapy in sickle cell disease. 
  • Effects of RSR13, a synthetic allosteric modifier of hemoglobin, alone and in combination with dizocilpine, on outcome from transient focal cerebral ischemia in the rat. 
  • Effects of a synthetic allosteric modifier of hemoglobin oxygen affinity on outcome from global cerebral ischemia in the rat. 
  • Effects of hydroxyurea treatment for patients with hemoglobin SC disease. 
  • Enalapril and hydroxyurea therapy for children with sickle nephropathy. 
  • Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. 
  • Hydroxyurea for Sickle Cell Disease: Now Is the Time! 
  • Hydroxyurea for secondary stroke prevention in children with sickle cell anemia in Nigeria: a randomized controlled trial. 
  • Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. 
  • Hydroxyurea for the treatment of sickle cell disease. 
  • Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children. 
  • Increased prevalence of osteonecrosis of the femoral head in children and adolescents with sickle-cell disease. 
  • Longitudinal follow up of elevated pulmonary artery pressures in children with sickle cell disease. 
  • Management of Sickle Cell Disease in Children. 
  • NIH consensus development statement on hydroxyurea treatment for sickle cell disease. 
  • National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. 
  • Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. 
  • Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. 
  • Patient-reported neurocognitive symptoms influence instrumental activities of daily living in sickle cell disease. 
  • Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia. 
  • RNA aptamer therapy for vaso-occlusion in sickle cell disease. 
  • Sequential development of human herpes virus 8-positive diffuse large B-cell lymphoma and chronic myelomonocytic leukemia in a 59 year old female patient with hemoglobin SC disease. 
  • Sickle-Cell Disease Co-Management, Health Care Utilization, and Hydroxyurea Use. 
  • Skin and nail changes in children with sickle cell anemia receiving hydroxyurea therapy. 
  • Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease. 
  • Tackling adherence in sickle cell disease with mHealth. 
  • The association of oral hydroxyurea therapy with improved cognitive functioning in sickle cell disease 
  • The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. 
  • Therapeutic strategies for sickle cell disease: towards a multi-agent approach.